株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乾癬性関節炎:パイプライン製品の分析

Psoriatic Arthritis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232834
出版日 ページ情報 英文 258 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
乾癬性関節炎:パイプライン製品の分析 Psoriatic Arthritis - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 258 Pages
概要

乾癬性関節炎(PA)は、乾癬に罹っている人の一部に合併して見られる関節炎です。手足の指の腫れ、足の痛み、腰痛などの症状が見られます。危険因子として、年齢、家族歴、乾癬患者が挙げられます。治療には、NSAID(非ステロイド性抗炎症薬)、免疫抑制剤、外科手術などが含まれます。

当レポートでは、乾癬性関節炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

乾癬性関節炎の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9367IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H1 2017, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 6, 9, 11, 2, 22, 7 and 4 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Psoriatic Arthritis - Overview
  • Psoriatic Arthritis - Therapeutics Development
  • Psoriatic Arthritis - Therapeutics Assessment
  • Psoriatic Arthritis - Companies Involved in Therapeutics Development
  • Psoriatic Arthritis - Drug Profiles
  • Psoriatic Arthritis - Dormant Projects
  • Psoriatic Arthritis - Discontinued Products
  • Psoriatic Arthritis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Psoriatic Arthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Psoriatic Arthritis - Pipeline by 3SBio Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by AbbVie Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by AbGenomics International Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Adello Biologics LLC, H1 2017
  • Psoriatic Arthritis - Pipeline by Allergan Plc, H1 2017
  • Psoriatic Arthritis - Pipeline by Alteogen Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Amgen Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Biocon Ltd, H1 2017
  • Psoriatic Arthritis - Pipeline by Bionovis SA, H1 2017
  • Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Psoriatic Arthritis - Pipeline by Coherus BioSciences Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2017
  • Psoriatic Arthritis - Pipeline by Formycon AG, H1 2017
  • Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H1 2017
  • Psoriatic Arthritis - Pipeline by Galapagos NV, H1 2017
  • Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Psoriatic Arthritis - Pipeline by Immunwork Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Innovent Biologics Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2017
  • Psoriatic Arthritis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Merck KGaA, H1 2017
  • Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Morphotek Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H1 2017
  • Psoriatic Arthritis - Pipeline by Nuevolution AB, H1 2017
  • Psoriatic Arthritis - Pipeline by Oncobiologics Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Psoriatic Arthritis - Pipeline by Pfizer Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Prothena Corp Plc, H1 2017
  • Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
  • Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2017
  • Psoriatic Arthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Psoriatic Arthritis - Pipeline by SynAct Pharma AB, H1 2017
  • Psoriatic Arthritis - Pipeline by UCB SA, H1 2017
  • Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H1 2017
  • Psoriatic Arthritis - Dormant Projects, H1 2017
  • Psoriatic Arthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Psoriatic Arthritis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Psoriatic Arthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top